Chairman of IFOM
Piero Sierra completes his studies in France, at the Faculty of Letters of the University of Lyon. He joined the Pirelli Group where he held executive positions in Italy, the United States and Brazil, until he became the Group's Chief Executive Officer. These tasks lead him to stay and travel extensively abroad.
Currently it is present on the Board of Directors of the main Pirelli offices in the world. He is passionate about photography and has participated in exhibitions and published various photography books, especially gardens.
From 2005 to 2014 Piero Sierra was Chairman of AIRC and FIRC-AIRC.
Born: Milan, April 2, 1926
A.:c/o IFOM, Via Adamello 16, I-20139 Milano
tel.: (+39) 02574303200
Educ.:1950, degree in medicine and surgery, Univ. of Milan; 1960, teaching qualification in anatomy and pathological histology; 1966, in experimental oncology
Car.:1951-55, worked at the Anatomical Pathology Institute, Univ. of Milan; 1956-60, associate researcher in chemical cancerogenesis, Experimental Oncology and Diagnostic Histopathology Divisions, Chicago Medical School (USA); his acquaintance with Pietro Buccalossi and Umberto Veronesi was fundamental in the establishment of the ACRO project (growth control of neoplasms), the Associazione Italiana per la Ricerca sul Cancro - AIRC (Italian Association for Cancer Research), Istituto Nazionale Tumori - INT (National Cancer Institute) and IFOM - FIRC Institute of Molecular Oncology (research centre on molecular oncology); 1961-70, head Experimental Carcinogenesis Section, INT; 1966-70, chmn. UICC Committee on Carcinogenesis; 1968, appointed board mem. SAES Getters S.p.A.; 1971-91, dir. Experimental Oncology Division, INT; 1979-83, pres. European Association for Cancer Research; 1980-82, pres. Immunology Cooperation Group; 1980-83, mem. scientific board International Agency for Research on Cancer, Lyon; 1985-91, deputy scientific dir. INT; 1992-2000, scientific dir. AIRC; 1994-2011, research coordinator European Institute of Oncology, Milan; 2001-07, board mem. Istituto Superiore di Sanità (Higher Institute of Health), Rome; at present, pres. IFOM - FIRC Institute of Molecular Oncology, Milan; vice-pres. Fondazione Italiana per la Ricerca sul Cancro - FIRC (Italian Foundation for Cancer Research) and AIRC; board mem. SAES Getters S.p.A.
Publs.: over 180 articles on various issues of experimental oncology, including experimental studies on chemical carcinogenesis, leukemogenesis, viral immunology and molecular biology of experimental and human tumours. See Survey: IFOM - FIRC Institute of Molecular Oncology
Gianpiero Sironi graduated as M.D. at the University of Milan in 1962, where he then started his research work. He has been research assistant at the Karolinska Institutet, Stockholm, Sweden (1965-1966) and at the University of California at Berkeley (1969). Since 1975 he has been full professor of Genetics at the University of Milano, where he has been Chairman of the Department of Genetics and Microbiology (1986-1990), Dean of the School of Biology (1990-1998), Chairman of the Ph.D. School in Genetics (1992-2001), Dean of the Faculty of Science (1998-2004) and Vice-Rector for Research (2004 ”“ 2009). He has been Chairman of the Conference of the Deans of the Schools of Biology of Italian Universities in 1990-1991 and President of the Italian Genetics Association (AGI) in 1990-1991.
His scientific interests, after an initial work on the induction of mutations in Drosophila, has dealt with various aspects of molecular genetics of bacteria, their plasmids, and bacterial viruses. Significant work has concerned the occurrence of prophage interference in lysogenic bacteria, the requirement of bacterial functions for phage multiplication and the physiology of a bacteriophage-plasmid element. He is a member of Istituto Lombardo, Academy of Sciences and Humanities. He retired form his University position in 2009, but is still interested in University life and its research activities.
Prof. Foiani has a Ph.D. in Molecular Biology from the University of Milan (Italy).
Since 2002, Prof. Foiani, who is also Head of the Genome Integrity Laboratory at IFOM since its establishment, is Full Professor in Molecular Biology at the University of Milan.
His research interest focuses on the regulatory mechanisms that control genome integrity. Particularly, his work has contributed to elucidate the cellular mechanisms causing genome instability in cancer cells and chromosome abnormalities in certain human syndromes leading to cancer predisposition. Prof. Foiani has more than 100 papers published in international scientific journals.
Since 2008 Prof. Marco Foiani is the Scientific Director of IFOM.
Prof. Foiani was honored with internationally recognized memberships and awards, such as: the European Molecular Biology Organization membership; the Academia Europaea membership; the New York Academy of Sciences membership; the Italian Society of Genetics (AGI) membership; the Italian Society of Biophisics and Molecular Biology (SIBBM) membership; the Award from the Italian Society for Biophysics and Molecular Biology (SIBBM); the Biotech Award promoted by Amgen and Dompé; the "Chiara D'Onofrio" Prize from the Italian Federation of Life Sciences.
He was the founder in 2009 of the European Nanomedicine Foundation (CEN) and vice-president up to 2011.
He’s been also member of the Scientific Advisory Board of AIRC, the Italian Cancer Research Association. Since 2009 he’s member of the editorial board of Cell and since 2010 he’s member of Academia Europaea.
Chief Financial Officer
Born in Milan in 1966 and graduate at Bocconi University in 1990. Davide Gremmi is a finance manager with over 25 years of experience in different sectors (research, biochemistry, engineering and banking) and with a significant exposure in the management of changes in an international environment.
Since 2017 he is the Administrative Director of IFOM. Previously he worked as CFO of GFBiochemicals Group, a biochemical start up with a breakthrough proprietary technology and as CFO of Chemtex Group, the engineering division of Mossi Ghisolfi Group with operation in Italy, USA, India and China.
After studying biochemistry at the University of Bayreuth, Ralf Adams started his research career at the Max-Planck-Institute for Brain Research and the Goethe University Frankfurt in Germany, where he obtained his Ph.D. in 1996. His work involved the cloning of new members of the semaphorin gene family and the characterization of their function in axon guidance.
Next, he moved to Rüdiger Klein's laboratory at the European Molecular Biology Laboratory in Heidelberg and began to work on the role of Eph/ephrin molecules in blood vessel morphogenesis. Together with his collaborator Angel Nebrada, he also investigated the function of the p38alpha mitogen-activated protein kinase.
In 2000, he became head of the Vascular Development Laboratory at the Cancer Research UK London Research Institute (formerly, Imperial Cancer Research Fund), where he and his laboratory made significant achievements by combining genetic approaches in the mouse with a wide range of cell and molecular biology methods. Several of their discoveries are directly relevant for human pathologies. For example, they were the first to show that the Eph receptor ligand ephrin-B1 controls skeletal morphogenesis and that defects in the human gene (EFNB1) lead to Craniofrontonasal Syndrome (CFNS). A different project has connected the cytoplasmic multi-PDZ domain protein GRIP1, an interaction partner of Eph/ephrin proteins and other molecules, with the rare but severe human congenital disease Fraser Syndrome. They also demonstrated that Junctional Adhesion Molecules (JAMs) are critical regulators of cell polarity.
Since he has moved as Director to the Max Planck Institute for Molecular Biomedicine and Professor the University of Münster in 2008, Ralf Adams and his group have continued to provide insight into key processes controlling developmental blood vessel growth and, in particular, its regulation by Notch, VEGF and Eph/ephrin signaling.
Geneviève ALMOUZNI, PhD (EMBO member, Member of the French Academy of Sciences, fellow of the American Association for the Advancement of Sciences, Director of the Research Center of the Institut Curie from sept. 2013 to sept. 2018 and honorary director since then) is director of research exceptional class at the CNRS. She is Principal Investigator of the Chromatin dynamics team in the Nuclear dynamics research Unit (UMR3664 CNRS/Institut Curie) since 1999. She is a world leader in understanding genome organization and function during development and disease in particular in cancer. She has combined biochemistry, cell biology and physical approaches with advanced imaging to explore chromatin dynamics. Active in the field of epigenetics and European actions, she coordinated the EpiGeneSys Network of Excellence to move epigenetics towards systems biology. She is highly engaged in promoting young scientist career. She received prestigious grants (ERC Advanced Grants) and awards including Woman in Sciences FEBS / EMBO (2013) and the grand prix FRM (2014). She served on the EMBO Council (Vicechair in 2014), ERC Council (2019), chair of the alliance EU-LIFE and co-chairs European FETFlagship initiative LifeTime.
Julian Downward obtained his bachelor's degree in Natural Sciences from Cambridge University and then studied for his Ph.D. in the laboratory of Michael Waterfield at the Imperial Cancer Research Fund in London, where he established in 1984 the link between a retroviral oncogene (v-erbB) and a cellular growth regulatory protein, the EGF receptor.
In 1986, he moved to Robert Weinberg's laboratory at the Whitehead Institute at the Massachusetts Institute of Technology in Cambridge, MA, where he began work on the role of Ras proteins in human cancer.
In 1989 he started his own lab at the Imperial Cancer Research Fund, now Cancer Research UK London Research Institute, where his lab has provided insights into the molecular mechanisms of function and regulation of oncogenic proteins of the Ras family and the importance of their mutational activation in human tumours.
In 2005 Julian was made a Fellow of the Royal Society, the UK's national academy of sciences, and became Associate Director of the Cancer Research UK London Research Institute.
Jan Hoeijmakers studied biology in Nijmegen. His PhD work on trypanosomes at the Univ. of Amsterdam resolved the molecular basis for antigenic variation by which trypanosomes switch each time surface coats and thereby escape from immune surveillance causing sleeping sickness.
In 1981 he joined the Dept. of Genetics of the Erasmus Univ. to work on DNA repair. He cloned the first of many subsequent human DNA-repair genes allowing elucidation of the reaction mechanism of nucleotide excision repair, discovered the strong evolutionary conservation of DNA repair, elucidated the basis of several enigmatic human repair syndromes, identified a new class of 'basal transcription disorders', generated a large number of DNA-repair mouse mutants that provided valuable insight into the complex etiology of human repair disorders and discovered a very strong, unanticipated link between DNA damage, repair and aging. Some of the repair mutants exhibit dramatically accelerated but bona fide aging limiting lifespan to only 3 weeks. Conditional mutants allowed targeting of accelerated aging to specific organs/stages of development (e.g. mouse mutants with dramatic aging only in the brain), making aging amenable to manipulation. Expression profiling revealed an unexpected similarity between short- and long-lived mice: both suppress the somatotrophic axis. This work led to the identification of a very important 'survival response' that promotes successful aging and counteracts cancer by redirecting energy from growth to defenses.
A new line of research explores the dynamic organization of DNA repair in living cells and intact organisms. His group generated the first mouse mutants with intrinsic defects in the biological clock. He owns several patents and discovered compounds that influence aging. His multi-disciplinary research has received several important awards.
In 2004 he started the 'DNage' whose mission is to provide solutions for medical/health problems associated with aging.
Dr Ish-Horowicz gained his PhD at the MRC Laboratory of Molecular Biology in Cambridge on tRNA structure, and conducted postdoctoral work on Drosophila molecular genetics with Walter Gehring at the Biozentrum in Basel, Switzerland. He then established his own lab at the Imperial Cancer Research Fund (now Cancer Research UK), initially at their Mill Hill site, then in Oxford and, finally, at the main ICRF/CR-UK Lincoln's Inn Fields laboratory in London. He is currently a Professor of Cell and Developmental Biology at University College London and a Visiting Scientist in the Biochemistry Department, Oxford University.
Dr Ish-Horowicz's studies has driven major advances in understanding the molecular processes that generate different cell-types in developing animals, in both Drosophila and vertebrate model systems. His work identified the first metazoan corepressor, Groucho/TLE, which regulates transcription in response to many signalling pathways, including Notch and Wnt. He also showed how molecular motors transport selected mRNAs along microtubules to help target asymmetric protein production within cells. In vertebrates, he demonstrated that Notch intercellular signalling acts in the nervous system to maintain neuronal stem cells and, thereby, to generate neuronal diversity. He also provided the first evidence that a cyclic transcriptional oscillator acts during vertebrate segmentation in order to produce regular reiterated body-structures such as the axial skeleton. For these and other findings, he was awarded the 1997 Gulbenkian Science Prize and the 2007 Waddington Medal of the British Society of Developmental Biology, and was elected a Fellow of the Royal Society in 2002.
Maria Jasin obtained a Ph.D. from the MIT and performed postdoctoral research at the University of Zürich and Stanford University. Her lab at Memorial Sloan Kettering Cancer Center performed the first gene editing experiment through generation of a DNA double-strand break (DSB) in the mammalian genome, demonstrating both gene correction and mutagenesis, and developed genetic and molecular assays to identify DSB repair events that continue to be widely used. These experiments established a crucial role for homologous recombination, also called homology-directed repair (HDR), as well as nonhomologous end-joining (NHEJ) in DSB repair.
With the approaches thus established, her lab determined that the breast cancer suppressors BRCA1 and BRCA2 are crucial in HDR repair, thus implicating HDR as a tumor suppression mechanism, and, further, that these proteins function at distinct steps in the pathway. Identification of their role in this pathway is being exploited in the treatment of BRCA1/2-deficient cancers. Her lab further established that BRCA1/2 and associated proteins play critical roles in the protection of stalled replication forks, and that BRCA2 is an essential gene for the suppression of replication stress. The lab also has a major effort directed at understanding the generation and repair of programmed DSBs during meiotic progression, which are essential for genome transmission, and in modelling cancer translocations.
Dr. Jasin is a member of the National Academy of Sciences, the National Academy of Medicine, and the American Academy of Arts and Sciences. She was awarded the Basser Global Prize for BRCA Research in 2018 and the Shaw Prize in Life Science and Medicine in 2019.
Professor Gordon McVie is widely regarded as a leading international authority in the research and treatment of cancer. Having qualified in the nineteen sixties in science and medicine at Edinburgh University, he was appointed Foundation Senior Lecturer at the Cancer Research Campaign oncology unit at the University of Glasgow in 1975. He trained in the US, and spent sabbaticals in Paris, Sydney and Amsterdam.
He is currently Clinical Research Adviser to the FIRC Institute of Molecular Oncology (IFOM), and is founding editor of ecancer.org, ecancerpatient.org and ecancerLatinoAmerica- online Open Access free websites. Recently he was Senior Consultant to the European Institute of Oncology, Milan. He is visiting professor at Cancer Studies, Kings College London.
Previously Professor McVie was Chief Executive of the Cancer Research Campaign (CRC), which, under his aegis, took over seventy molecules from the lab into clinical trial. He led CRC into a merger with Imperial Cancer Research Fund which formed Cancer Research UK, in 2002, and was joint CEO with Sir Paul Nurse.
Throughout the Eighties, he was Clinical Research Director at the National Cancer Institute of the Netherlands. As President of EORTC, he set up the present Drug Development Group in Brussels, and with NCI support, the European New Drug Development Network. He followed Sir Walter Bodmer as Chair of the UICC Fellowships Programme in 1990 and held the post for eight years.
In the UK he was one of the architects of the Cancer Trials Networks in Scotland, Wales, and England, and was a founding member of the National Cancer Research Institute.
Professor McVie is the recipient of numerous awards and has honorary doctorates in science from six universities. He has served on key committees of AACR and ASCO, and on the boards of the National Cancer Institutes of France, Italy, and Holland. He has authored 360 peer-reviewed articles, and contributed to over 35 books.
His commitment to drug discovery and delivery is evidenced by approximately 240 patents granted to CRC scientists under his leadership, several drugs registered including carboplatin, temozolomide and abiraterone and the foundation of 10 biotechnology companies based on CRC intellectual property. His clinical interests, apart from new drug discovery and chemoprevention, are in the management of cancers of the lung, ovary, liver, breast and brain. He is a nonexecutive director of a Danish start-up company, Nanovi. He is a partner with ecancer in 3 FP7 projects from the European Union and a recently awarded Horizon 2020 project.
He was elected as Fellow of the European Association for Cancer Science in 2014, and has been chairman of the European Alliance for Personalised Medicine since early 2016.
He lives in Bristol, UK, with his wife Claudia who is Chief Executive of the cancer charity Tenovus Cancer Care.
Klaus Rajewsky developed a general method of targeted mutagenesis in mouse embryonic stem cells by introducing bacteriophage- and yeast-derived recombination systems, which opened the way for conditional gene targeting. Using this and other methods in his immunological work, he developed, together with N. A. Mitchison and N. K. Jerne, the antigen-bridge model of T-B cell cooperation, identified germinal centers as the sites of antibody somatic hypermutation, the B cell antigen receptor as a survival determinant of B cells, and the germinal center as a major site of human B cell lymphomagenesis, including Hodgkin lymphoma. Over the last years the work of his group has focused on mechanisms of microRNA control and the development of mouse models of human B cell lymphomas.
After postdoctoral work at the Institut Pasteur in Paris he built an immunology department at the Institute for Genetics at the University of Cologne, where he stayed for 38 years, was the founding Program Coordinator of the EMBL Mouse Biology Program at Monterotondo near Rome, worked for 10 years at Harvard Medical School in Boston, and is since 2012 at the Max-Delbrück-Center for Molecular Medicine in Berlin, Germany.
Klaus Rajewsky won numerous scientific awards and is a member of several learned societies including the National Academy of Sciences of the USA and the American Academy of Arts and Sciences.